NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine

May 28, 2015

Off

Share This

GSK reports over 97% efficacy for their QS-21 containing Shingles vaccine in a large Phase III trial enrolling a total of 15,411 participants, with a mean follow up of 3.2 years.

Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine

leroux-roels_1-s2.0-S0264410X14014698-main

Vaccine Adjuvant Systems containing monophosphoryl lipid A andQS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination

Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol

Nature Chemistry: Development of a minimal saponin vaccine adjuvant based on QS-21

NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine

Related Posts

Recent Posts

Archives

Categories